Neuro-Oncology News

The incidence of brain metastases among patients with nonmetastatic lung cancer varies according to patient characteristics such as age, sex and histology, according to results of an observational study.

Coffee no longer should be classified as carcinogenic to humans, according to a working group from WHO’s International Agency for Research on Cancer.

This year’s ASCO Annual Meeting featured the theme “Collective wisdom: The future of patient-centered care and research.”

CHICAGO — Extending anticoagulation beyond 3 months reduced risk for recurrent clots in patients with cancer, according to results presented at the ASCO Annual Meeting.

CHICAGO — Despite global variance in cancer drug prices, generic and patented drugs are less affordable in low-income countries, according to a pilot study presented at the ASCO Annual Meeting.

CHICAGO — The addition of a second autologous hematopoietic stem cell transplantation to standard therapy improved survival outcomes for children with high-risk neuroblastoma, according to phase 3 trial results presented during the plenary session of the ASCO Annual Meeting.

CHICAGO — The addition of concomitant and adjuvant temozolomide to hyperfractioned radiation therapy significantly improved PFS and OS among older patients with newly diagnosed glioblastoma, according to phase 3 study results presented during the plenary session of the ASCO Annual Meeting.

CHICAGO — Liquid biopsy identified genomic alterations in patients with advanced solid tumors at a similar rate to traditional tumor biopsy, according to data presented at the ASCO Annual Meeting.

CHICAGO — The addition of a novel anti-GD2 monoclonal antibody to an intensive chemotherapy regimen significantly improved the response rate in pediatric patients with high-risk neuroblastoma, according to results of interim analysis of a phase 2 study presented at the ASCO Annual Meeting.

CHICAGO — Twelve cycles of adjuvant temozolomide extended OS and PFS among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletion, according to early results from the phase 3 CATNON trial presented at the ASCO Annual Meeting.